sign in · help · news · about ·

BibSonomy :: user :: kanefendt ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

>
|
<

bookmarks

bookmarks per page: 5 10 20 50 100

RSS BibTeX RDF more

publications

(50)

<< < 1 | 2 | 3 > >>

Sunitinib efficacy against advanced renal cell carcinoma
R. J. Motzer, M. D. Michaelson, J. Rosenberg, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, and G. Wilding J.Urol. 178(5):1883-1887 (2007)
to & Administration Adult Aged Agents Antineoplastic Carcinoma Cell Disease Disease-Free Female Follow-Up Humans Indoles Kidney Laboratories Male Method Middle Neoplasm Neoplasms Oral Outcome Progression Pyrroles Rate Renal Research Retrospective Single-Blind Staging States Studies Survival Treatment Tyrosine United administration dosage drug epidemiology methods mortality pathology response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor
A. P. Dei Tos Int.J.Biol.Markers 22(1 Suppl 4):S3-S9 (2007)
to Antibodies Biological Epidermal Expression Factor Gene Growth Human Humans Immunohistochemistry Markers Monoclonal Neoplasms Neoplastic Prognosis Receptor Regulation Tyrosine analysis drug effects etiology identify pathology physiology response therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib
S. E. Deprimo, and C. Bello Ann.Oncol (2007)
to Angiogenesis Biological Cells Endothelial Growth Humans Indoles Inhibitors Laboratories Markers Neoplasms Neovascularization Pathologic Proteins Pyrroles Research Tumor blood cells diagnosis drug effects metabolism methods pathology pharmacology protein response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges
F. Cappuzzo, L. Toschi, G. Finocchiaro, C. Ligorio, and A. Santoro Int.J.Biol.Markers 22(1 Suppl 4):S10-S23 (2007)
to & Antibodies Biological Carcinoma Dosage Drug Epidermal Factor Gene Growth Human Humans Immunohistochemistry Inhibitors Kinase Kinases Lung Markers Monoclonal Mutation Neoplasm Neoplasms Non-Small-Cell Phosphoproteins Predictive Protein Protein-Tyrosine Proteins Proto-Oncogene Quinazolines Receptor Resistance Tests Tyrosine Value analysis antagonists c-akt drug effects erbB-2 erbB-3 genetics identify inhibitors of protein response therapeutic therapy use by kanefendt and 1 other user on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel Deprimo, Carlo Bello, John Smeraglia, Charles Baum, Dominic Spinella, Brian Rini, M. Dror Michaelson, and Robert Motzer Journal of Translational Medicine 5(1):32 (2007)
to Carcinoma Disease Placenta Progression Proteins Tyrosine analysis protein response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Appropriate calibration curve fitting in ligand binding assays
J. W. Findlay, and R. F. Dillard AAPS.J. 9(2):E260-E267 (2007)
to & Algorithms Analytical Binding Calibration Chemistry Dose-Response Drug Ligands Models Pharmaceutical Pharmacokinetics Preparations Protein RANGE Relationship Reproducibility Research Results Sensitivity Specificity Statistical analysis and data metabolism methods numerical of response statistics by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
T. Force, D. S. Krause, and R. A. van Etten Nat.Rev.Cancer 7(5):332-344 (2007)
to & Adaptor Antibodies Benzenesulfonates Biological Delivery Diseases Drug Enzyme Heart Human Humans Indoles Inhibitors Kinase Kinases Models Monoclonal Mutation Neoplasms Protein Protein-Tyrosine Proteins Proto-Oncogene Pyridines Pyrroles Quinazolines Research Signal Systems Transducing Tyrosine adverse antagonists c-abl cells chemically development drug effects growth induced inhibitors physiology protein response therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel Proc.Natl.Acad.Sci.U.S.A 104(43):17069-17074 (2007)
to & A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular basis for sunitinib efficacy and future clinical development
S. Faivre, G. Demetri, W. Sargent, and E. Raymond Nat.Rev.Drug Discov. 6(9):734-745 (2007)
to & A Angiogenesis Animals Carcinoma Clinical Design Drug Endothelial Factor France Growth Humans Indoles Inhibitors Kinase Kinases Neoplasm Neoplasms Protein-Tyrosine Pyrroles Receptors Resistance Topic Trials Tyrosine Vascular adverse antagonists as biosynthesis blood drug effects enzymology inhibitors metabolism pharmacology response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment
A. Gampel, L. Moss, M. C. Jones, V. Brunton, J. C. Norman, and H. Mellor Blood 108(8):2624-2631 (2006)
to A Active Adult Biological Blood Cell Cells Compartmentation Cultured Endosomes Endothelial Factor GTP-Binding Growth Humans Kinases Laboratories Lysosomes Membrane Plasma Proteins Receptor-2 Recombinant Research Transport Tyrosine Vascular Vessels blood cells cytology drug effects metabolism pharmacology protein rab4 response src-Family by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
M. Shibuya, and L. Claesson-Welsh Exp.Cell Res. 312(5):549-560 (2006)
to Aging Animals Cell Cells Development Division Embryonic Endothelial Endothelium Factor Growth Human Humans Japan Ligands Lymphangiogenesis Lymphatic Lymphedema Neovascularization Pathologic Physiologic Placenta Receptor-1 Receptor-2 Research Signal System Transduction Tyrosine Vascular Vertebrates cells cytology genetics physiology physiopathology response by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis
M. Shibuya J Biochem.Mol.Biol. 39(5):469-478 (2006)
to A Animals Atherosclerosis Cells Chemistry Development Dna Embryonic Endothelial Factor Female Growth Human Humans Inflammation Japan Metastasis Mice Neoplasm Neoplasms Neovascularization Pathologic Physiologic Pre-Eclampsia Pregnancy Proteins Receptor-1 Receptor-2 Research Signal Transduction Tyrosine Vascular Viral blood cells genetics metabolism physiology physiopathology protein response supply therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
B. Vincenzi, D. Santini, A. Russo, M. Gavasci, F. Battistoni, G. Dicuonzo, L. Rocci, V. M. Rosaria, N. Gebbia, and G. Tonini Pharmacogenomics. 8(4):319-327 (2007)
to & A Adult Aged Antibodies Antineoplastic Biological Camptothecin Chemotherapy Colorectal Combined Disease Endothelial Factor Female Growth Humans Male Markers Medical Middle Monoclonal Neoplasms Oncology Outcome Progression Prospective Protocols Rate Studies Survival Treatment Tumor Vascular administration analogs antagonists blood derivatives dosage drug inhibitors methods mortality response therapeutic therapy trends use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer
S. E. Deprimo, C. Friece, X. Huang, J. Smeraglia, L. Sherman, M. Collier, C. Baum, A. D. Elias, H. J. Burstein, and K. D. Miller J Clin Oncol Meeting Abstracts 24(18_suppl):578 (2006)
to Outcome Proteins Research SU11248 Treatment Tyrosine analysis methods protein response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity
E. Carcereny, and J. Maurel Rev.Recent Clin.Trials 1(2):113-118 (2006)
to & Animals Antibodies Biomarkers Carcinoma Colorectal Drug Epidermal Europe Factor Factors Growth Humans Immunologic Ligands Medical Monoclonal Mutation Neoplasm Neoplasms Oncology Pharmacological Phosphorylation Prognosis Receptor Resistance Tyrosine antagonists genetics inhibitors pharmacology response therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Prognostic markers and new, innovative treatments in renal cell carcinoma
C. C. Secasan Saudi.J.Kidney Dis.Transpl. 20(3):355-361 (2009)
to Carcinoma Research Tyrosine response surgery by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?
J. Wood, E. Scott, and A. L. Thomas Expert.Opin.Investig.Drugs 18(11):1701-1714 (2009)
to Growth Tyrosine response toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh, C. Dive, and G. C. Jayson Br.J.Cancer (2009)
to Blood Growth Health Medical Oncology Plasma Pressure Prospective Research Studies blood identify response by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Clinical biomarkers of angiogenesis inhibition
A. P. Brown, D. E. Citrin, and K. A. Camphausen Cancer Metastasis Rev. 27(3):415-434 (2008)
to Angiogenesis Human Inhibitors Research response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. Deprimo, C. M. Baum, and K. D. Miller J Clin Oncol 26(11):1810-1816 (2008)
to & Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)

<< < 1 | 2 | 3 > >>publications per page: 5 10 20 50 100

a gripper